Pegvisomant
- Generic Name
- Pegvisomant
- Brand Names
- Somavert
- Drug Type
- Biotech
- CAS Number
- 218620-50-9
- Unique Ingredient Identifier
- N824AOU5XV
Overview
Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
Background
Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
Indication
Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.
Associated Conditions
- Acromegaly
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.